Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.40 |
| ▸ | MAOB | P27338 | 8/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL5175074 | 0.97 | NPC1 (0.48) | NPC1RAB9AMAPTAPPLMNA | |
| SCHEMBL25870778 | 0.91 | NPC1 (0.44) | NPC1RAB9AMAPTAPPLMNA | |
| SCHEMBL779443 | 0.89 | NPC1 (0.58) | NPC1RAB9AMAPTLMNAMAPK1 | |
| Sulfuric Acid SCHEMBL2773087 | 0.87 | NPC1 (0.43) | NPC1RAB9AMAPTAPPLMNA | |
| Sulfuric Acid SCHEMBL2773086 | 0.87 | NPC1 (0.43) | NPC1RAB9AMAPTAPPLMNA | |
| SCHEMBL6282371 | 0.82 | APP (0.41) | NPC1RAB9AMAPTAPPLMNA | |
| SCHEMBL12967599 | 0.82 | NPC1 (0.48) | NPC1RAB9AMAPTLMNAMAPK1 | |
| SCHEMBL26844942 | 0.82 | ESR1 (0.45) | NPC1RAB9AMAPTAPPLMNA | |
| SCHEMBL5552840 | 0.81 | NPC1 (0.52) | NPC1RAB9AMAPTLMNAMAPK1 | |
| SCHEMBL3625528 | 0.81 | NPC1 (0.52) | NPC1RAB9AMAPTAPPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907182-A | Clean preparation method of 4-iodo-tert-amylbenzene | 武汉诺安药业有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-110498729-A | Clean preparation method of amorolfine hydrochloride intermediate | WUHAN NUOAN PHARMACY CO LTD | 2019-11-26 | — | — | CN | claimed |
| CN-102321212-B | Polymkeric substance, chemical-amplification positive anti-corrosion agent composition and pattern formation method | SHIN-ETSU CHEMICAL INDUSTRY CO., LTD. (JP) | 2015-08-19 | — | — | CN | claimed |
| US-20090131660-A1 | SYNTHESIS OF 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND cis-4--2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | GALDERMA S.A. (CH) | 2009-05-21 | — | — | US | claimed |
| EP-2007742-A1 | PROCESS FOR PRODUCING 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND CIS-4-{3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPYL}-2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | Galderma S.A. (CH) | 2008-12-31 | — | — | EP | claimed |
| WO-2007113218-A1 | PROCESS FOR PRODUCING 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND CIS-4-{3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPYL}-2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | GALDERMA S.A. (CH) | 2007-10-11 | — | — | WO | claimed |
| EP-1842848-A1 | Process for producing 3-[4-(1,1-dimethyl-propyl)-phenyl]2-methyl-propionaldehyde and cis-4{3-[4-(1,1-dimethyl-propyl)-phenyl]2-methyl-propyl}-2,6-dimethyl-morpholine (amorolfine) | Galderma S.A. (CH) | 2007-10-10 | — | — | EP | claimed |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436976-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118510783-A | Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-116954024-A | Chemically amplified positive resist composition and method for forming resist pattern | 信越化学工业株式会社 | 2023-10-27 | — | — | CN | disclosed |
| CN-111665684-B | Positive resist composition and pattern forming method | 信越化学工业株式会社 | 2023-08-25 | — | — | CN | disclosed |
| US-20230242689-A1 | POLYMER, COPOLYMER, INK, INK CONTAINER, IMAGE FORMING METHOD, IMAGE FORMING DEVICE, AND BACKSHEET FOR SOLAR CELL | RICOH COMPANY, LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-7157206-B2 | Resin containing an acid-decomposable group such as bis(trifluoromethyl)methanol group, to generate alkali-soluble group, and acid generators selected from fluorine-substituted or non-fluorine substituted aromatic or aliphatic carboxylic acid generators or sulfonic acid generators; microlithography | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157208-B2 | Positive resist composition and pattern forming method using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1249840-C | Nonaqueous electrolyte solution and lithium secondary battery | UBE INDUSTRIES (JP) | 2006-04-05 | — | — | CN | disclosed |
| CN-1662853-A | Onium salts and their use as latent acids | CIBA SC HOLDING AG (CH) | 2005-08-31 | — | — | CN | disclosed |
| US-20040121239-A1 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| CN-1498438-A | Nonaqueous electrolyte solution and lithium secondary battery | ��˲���ʽ���� | 2004-05-19 | — | — | CN | disclosed |
| EP-1361622-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | Ube Industries, Ltd. (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | NPC1 10/4885RAB9A 1495/4885MAPT 1090/4885 |
| US-20090131660-A1 | SYNTHESIS OF 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND cis-4--2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | PDK2, EML4, DEK | NPC1 4535/4885RAB9A 4501/4885MAPT 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.